Introduction
The outcome for younger patients with acute myeloid leukemia (AML) has improved over the last 20 years. 1 However, patients over the age of 60 years, who comprise the majority of the individuals with AML, have not benefited as much. When treated with conventional chemotherapy, these older patients have a 20% 2-year and 10% 5-year survival. [2] [3] [4] [5] [6] [7] [8] These disappointing outcomes reflect an increased frequency of poor-risk cytogenetics, a higher incidence of antecedent myelodysplasia, higher MDR1 protein expression and a limited ability to tolerate aggressive chemotherapy. 9, 10 Harnessing the immune effect 11 of allogeneic hemopoietic stem cell transplantation (SCT) may improve outcome in this resistant disease, but many older patients are unsuited to conventional SCT because of increased transplant-related mortality. Allogeneic transplantation using reduced-intensity conditioning regimens (reduced intensity SCT (RISCT)) may be an alternative, but in older patients there may be a higher risk of severe graft-versus-host disease (GVHD) or of rejection. In this study, we report the outcome of RISCT for a group of high-risk and older patients with AML. To reduce the increased risks of GVHD and of graft rejection in the older patient, we incorporated lymphodepleting antibodies into the conditioning regimen. The outcome in this unselected group suggests the value of this approach, even in high-risk patients lacking MHC-identical sibling donors.
Patients and methods
Patients with high-risk AML were recruited into the study if they had HLA A, B and DRB1 fully (6/6) matching sibling (n ¼ 5) or an alternative donor who was a one antigen-mismatched (n ¼ 3) or a fully HLA-matched unrelated individual (n ¼ 9). The HLA A and B antigens were typed by intermediate-resolution DNA typing with equivalent sensitivity to serologic typing, and DRB1 was typed by high-resolution DNA analysis. All patients were ineligible for myeloablative transplantation because of age or comorbid illness (Table 1) . Eleven of 17 patients had a Charlson Comorbidity Index score of X1, 12 but all 17 patients had an abnormal score of X1, according to the more recent and more sensitive Hematopoietic Cell Transplantation Specific Comorbidity Index, 13 with 12 patients in the high-risk group (score X3) and five patients in the intermediate-risk group (score 1 or 2). Patients were ineligible if they were HIV positive, had unstable angina, decompensated congestive heart failure, severe pulmonary disease requiring oxygen, stroke in the previous 6 months or Child's class C cirrhosis. All patients were treated at a single institution on IRB-approved protocols, and all patients signed an informed consent. Outcomes were reviewed by a Data Safety Monitoring Committee.
Patient characteristics
Detailed characteristics of the 17 consecutive patients enrolled in the study are shown in Tables 1 and 2 . The 11 males and six females had a median age of 58 years (range 28-75 years) and had high-risk disease as indicated by antecedent myelodysplastic syndrome, or myeloproliferative disease, active leukemia or second remission at the time of transplant or a karyotype indicating poor prognosis. For four patients, the stem cell source was the bone marrow; for the remaining 13 patients, mobilized peripheral blood stem cells were used. The median number of CD34 þ cells infused was 6.39 Â 10 6 /kg (range 1.09-14.0 Â 10 6 /kg).
Conditioning regimens
All patients received total body radiation 450 cGy in a single fraction (day À6) and fludarabine 30 mg/m 2 daily (days À5 to À2). All patients also received a lymphodepleting antibody depending on the date of the transplant. The earliest patients (n ¼ 3) received antithymocyte globulin (ATG-Atgam, Pharmacia and Upjohn) 10 mg/kg/day (days À5 to À2). The second cohort of eight patients received alemtuzumab 10 mg/daily (days À5 to À2). The final cohort also received monoclonal antibodies targeting CD45. These anti-CD45 antibodies are short lived, and were intended to further deplete host immunity to prevent rejection, while sparing the donor T cells, to favor both complete donor chimerism and a graft-versus-leukemia effect. 14, 15 In this last group of patients, alemtuzumab (10 mg) was given daily on days À8 to À6, and CD 45 monoclonal antibodies (0.4 mg/kg) were given daily on days À5 to À2. All patients received Tacrolimus post transplant, to reach targeted serum levels of 5-15 ng/ml. Patients were nursed in HEPA-filtered rooms with standard supportive care, and were given antimicrobial prophylaxis with levofloxacin, fluconazole and acyclovir. After engraftment, patients received ganciclovir (if at risk of CMV reactivation) immunoglobulins, and cotrimoxazole.
Study end points
The major study end point was sustained allogeneic engraftment. Secondary outcomes included the incidence and severity of GVHD, nonrelapse mortality, progressionfree and overall survival. Neutrophil recovery was defined as the first of 3 consecutive days with a neutrophil count more than 0.5 Â 10 9 /l. Platelet recovery was defined as the first of 3 consecutive days with a platelet count of more than 20 Â 10 9 /l without support. Graft rejection was defined as absence of any donor cells on chimerism studies. GVHD, disease response and progression were defined by standard criteria.
Statistical analysis
Data were summarized using descriptive statistics. Overall and progression-free survival were calculated using the Kaplan-Meier method. Cumulative incidences were calculated using NCSS 2004 software (NCSS Kaysville, UT, USA) for GVHD and CMV reactivation; death and graft rejection were treated as competing events. 16 Immune reconstitution studies Peripheral blood samples for post transplant follow-up were collected according to protocol-specific roadmaps from 11 patients. The following three-color panels were used in the identification of the lymphocytes and lymphocyte subsets:
PE for threepart differential, and (6) Cells þ Flow Buffer served as the negative control. Cell Quest was used as the acquisition and analysis software, and 20 000 total events were acquired with a FACScan single 400 nm laser flow cytometer (BD Biosciences Immunocytometry Systems, San Jose, CA, USA). Standard analysis templates were created for the evaluation of each of the lymphocyte subsets following Boolean logic for the gating strategy and using the CD45POSITIVE cells as the primary trigger region. The mean percentage of the CD3 replicates was reported and all samples had an absolute difference of o2% and CV of o1%. Each sample was checked to ensure that the T-B-NK populations were equivalent to the total lymphocytes and that the CD4 þ CD8 subsets were 495% of total CD3 positive cells. The absolute numbers of each lymphocyte subset were calculated as cells Â 10 
Results

Engraftment and chimerism
Outcomes are summarized in Table 3 . All patients engrafted; neutrophil recovery (absolute neutrophil count greater than 0.5 Â 10 9 /l) occurred at a median of 11 days (range 4-25 days), while platelet engraftment (platelet count greater than 20 Â 10 9 /l) was at day 20 (range 11-205 days). Chimerism studies at day 30 showed that 15 of 17 patients had 100% donor peripheral blood mononuclear cells and granulocytes. Of the two patients with mixed chimerism, one converted to 100% donor chimerism on tacrolimus withdrawal, and the other had early relapse. No association between mixed chimerism and relapse was seen in this study. Of the seven patients alive disease free, two have mixed chimerism and the remaining five have 100% donor hematopoiesis at the time of most recent follow-up.
Graft-versus-host disease
The cumulative incidence of grade II-IV acute GVHD (n ¼ 4) was 29% (95% CI, 14-61%), but only one patient (cumulative incidence 6%) developed severe grade III-IV acute GVHD, which was fatal. Five patients subsequently developed chronic GVHD, which was extensive in one and limited in four for a cumulative incidence of 29% (95% CI, 14-61%).
Infection and immune reconstitution
One patient died of Staphylococcus aureus sepsis (1) and one from disseminated toxoplasmosis. Cytomegalovirus (CMV) infection developed at a median of 35 days post transplant (range 5-138 days) in 10 patients with a cumulative incidence of 59% (95% CI, 40-88%). However, none of the patients developed CMV disease or EBV lymphoproliferative disorder despite profound lymphocytopenia. Recovery was the fastest for NK cells, intermediate for B cells and CD8 T cells, and slowest for CD4 T cells (Figure 1 ). Long-term outcome After a median follow-up of 861 days (372-1957 days), seven patients have relapsed and seven are disease-free survivors, to give an actuarial progression-free survival and overall survival of 40% (95% CI 17-64%) (Figure 2 ). The overall nonrelapse mortality due to GVHD and infection was 18%.
Discussion
We have shown that transplantation using reducedintensity conditioning with lympholytic antibodies is a feasible option for patients with AML who, owing to reasons of age or comorbidity, are unsuitable for conventional SCT. Of our 17 patients with a median age of 58 years, the majority had at least one disease feature indicative of a particularly high risk of failure after conventional treatment. The cohort included nine patients (57%) with secondary AML, 10 with poor-risk cytogenetics (59%) and 11 in relapse or second remission (63%). These adverse features notwithstanding, all patients engrafted, the overall nonrelapse mortality was 18% and progression-free survival at a median 861 days is 40%. Although remarkable progress has been made in understanding the biology of AML in older patients, up until recently the prognosis and outcome of these patients have remained dismal, with fewer than 10% surviving long term. In older patients, the disease is often inherently 17, 18 and this may also be the mechanism by which RISCT achieves its benefits in these patients. As our study was targeted at older patients, the majority (71%) of whom lacked MHC-identical siblings as stem cell donors, we reasoned that the greatest risk of treatment-related morbidity and mortality would come from graft rejection and GVHD. Accordingly we developed sequential Phase I protocols to assess the feasibility of incorporating lymphodepleting MAb. We began with the polyclonal ATG, substituting the mononclonal antibody alemtuzumab, which targets CD52 as it became available. The use of these antibodies pre-transplant serves to deplete host immune cells, thereby reducing the risk of graft rejection. Both ATG and alemtuzumab also remain in circulation after infusion of donor marrow and therefore deplete donor lymphocytes, reducing the incidence of GVHD. 19, 20 To further reduce the risk of rejection, our final cohort of patients also received anti-CD45 MAbs. These antibodies have an extremely short half-life (8 h) and serve to reduce host lymphopoiesis additionally while sparing the subsequently infused donor T cells: hence, their addition should facilitate engraftment without compromising the putative graft-versus-leukemia activity from the donor cells. 14, 15, 21 Although this study was not designed or intended to compare the relative effectiveness of these lymphodepleting antibodies, it is evident that in aggregate they appear to have acted as hoped: all patients engrafted-including those receiving an MHC-mismatched or -unrelated donor transplant -and all but one became full donor chimeras without requiring donor lymphocyte infusion, while nonrelapse mortality (including GVHD) was 18%. Both outcomes appear superior to those reported previously using RISCT regimens without monoclonal antibodies. These studies had a rejection rate of 6-21% and a severe GVHD rate of 10-20%, [22] [23] [24] [25] compared to the rejection rate of 0% and severe GVHD rate of 6% seen in this study. Despite the high-risk disease and use of alternative donors cells for the majority of patients, the progression-free survival was 40% compared to 32-61% reported in the other studies of RISCT for AML, some of which also used ATG. 22, [25] [26] [27] [28] In summary, RISCT that incorporates lymphodepleting antibodies may improve long-term survival in older patients with AML, including those with high-risk disease who lack an MHC-identical sibling donor. 
